Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JV GL1

Next Previous
X
Search
Drug Profile

JV GL1

Alternative Names: JV-GL1

Latest Information Update: 22 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator JeniVision
  • Class Antiglaucomas; Eye disorder therapies
  • Mechanism of Action Prostaglandin E EP2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Ocular hypertension; Open-angle glaucoma

Most Recent Events

  • 10 May 2024 JeniVision terminates a phase-I/II trial in Open-angle glaucoma in USA (Ophthalmic) due to awaiting transition to part 2 (NCT04761705)
  • 10 Mar 2021 Phase-I/II clinical trials in Ocular hypertension in USA (Ophthalmic) (NCT04761705)
  • 24 Feb 2021 Preclinical trials in Ocular hypertension in USA (Ophthalmic) prior to February 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top